Cerenome reports no dose-limiting toxicities in interim REYOBIQ repeat-dose study
CNSY•Cerenome said the first 10 patients in its interim ReSPECT-LM study experienced no dose-limiting toxicities or adverse events leading to treatment discontinuation. Enrollment and dose escalation are ongoing, and a randomized Phase 2 study is targeted for 2027, subject to clinical progress and regulatory alignment.
1. Interim safety findings
Cerenome presented interim ReSPECT-LM results supporting repeat REYOBIQ dosing for leptomeningeal metastases at the SNO meeting on November 13, 2026. The first 10 patients experienced no dose-limiting toxicities or adverse events leading to treatment discontinuation.
2. Early follow-up
No disease progression was documented among evaluable patients at early follow-up milestones, although progression occurred in one patient at a later assessment. The preliminary findings do not establish a survival benefit, and enrollment and dose escalation remain ongoing.
3. Next study target
A randomized Phase 2 study is targeted for 2027, subject to clinical progress and regulatory alignment.




